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E-mail address: dzimiri@kfshrc.edu.sa (N. Dzimiri)Background: Heterogeneous familial hypercholesterolemia (HFH) partly underlies polymorphic changes
in the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB) and protein convertase subtili-
sin/kexin type 9 (PCSK9), exhibiting intra-ethnical variations in its clinical features.
Methods: We employed the Affymetrix whole genome scan 250 sty1 array to characterize possible geno-
mic linkage to heterozygous familial hypercholesterolemia (HFH) and sequencing techniques to identify
related mutations in the above three genes in a Saudi family of 11 individuals harbouring clinical features
of FH. The propositus had early onset of coronary artery disease (CAD) and very signiﬁcantly elevated
cholesterol (Chol) level of 10.1 mmol/L and LDL-cholesterol (LDL-C) of 7.9 mmol/L as well as low HDL-
C level of 0.51 mmol/L, while 4 siblings were affected with HFH.
Results: Whole genome scan for the autosomal dominant model showed high homology for the affected
individuals in several regions including chromosomes (chr) 1 and 2 which harbour PCSK9 and APOB,
respectively. Subsequent sequencing of the coding regions of these two and LDLR identiﬁed 11 single
nucleotide polymorphisms (SNPs) in the LDLR, 8 in the APOB and 6 in the PCSK9 genes. The propositus
uniquely carried the homozygous mutant genotypes (haplotype) for all 11 LDLR SNPs, in direct contrast
to the only normolipidemic sibling and a control who carried the homozygous wild type genotypes at
these loci. Another set of 7 SNPs in the APOB also isolated with FH. Interestingly, all family members were
heterozygous for all except the rs2228671 C > T of this gene, for which the mother shared the C/C geno-
type with the propositus, two other affected off-springs and a control, all of whom exhibited low HDL-C
levels. A conﬁrmation experiment involving 70 individuals harbouring low HDL-C revealed 74.3% of them
as C/C carriers.
Conclusions: Our study identiﬁed a haplotype in the LDLR as a marker for early onset of CAD, and
rs2228671 C > T in the LDLR in association with a reduction in HDL-C concentrations in FH. The results
also substantiate the notion of genetic heterogeneity in HFH, underlining the essence of recognizing eth-
nic-speciﬁc gene variability as a potential basis for appropriate management of FH.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
The low-density lipoprotein (LDL) receptor (LDLR) is the key
component in the maintenance of cholesterol (Chol) homeostasis
in the body, as a pivotal regulator of the hepatic catabolism of
LDL-cholesterol (LDL-C) [1–3]. Familial hypercholesterolemia
(FH) is triggered by defective catabolism of these lipoproteins,
eventually progressing to premature atherosclerosis and early cor-
onary artery disease (CAD). It is an autosomal dominant genetic
disorder caused by, more often than not, a partial or total lack ofellitus. Published by Elsevier Ltd. O
: +966 1 4424585.
.functional LDLRs [1]. Both homozygous and heterozygous pheno-
types of the disease have been described, whereby the homozy-
gous form is rare and the heterozygous is common [2,3].
However, the later remains under-diagnosed worldwide. The clin-
ical phenotype of heterozygous FH (HFH) is characterized by in-
creased plasma levels of total Chol and LDL-C, tendinous
xanthomata, and symptoms of premature CAD. It is inherited as
an autosomal dominant hypercholesterolemia (ADH), a frequent
monogenic disorder characterized by isolated elevation of LDL-C
inducing premature cardiovascular disease, with homozygotes
having a more severe phenotype than the heterozygotes. The dis-
ease is commonly known to result from mutations in two primary
genes: the LDLR [3–14] and its natural ligand, the apolipoproteinpen access under CC BY-NC-ND license.
Table 1
Important clinical and demographic characteristics of the studied groups and CAD
groups.
Candidate Sex Age Chol TG LDL-C HDL-C
FT 1 40 6.1a 0.8 4.0 1.06
MT 2 40 6.3b 0.5 4.2b 1.04
S1 1 20 5.3 0.4 3.6 0.86b
S2 1 17 3.1 0.2 1.5 1.35
S3 1 14 10.1b 0.3 7.9b 0.51b
S4 1 12 6.2a 1.0 4.4b 0.98b
S5 1 10 4.7 0.6 2.6 1.36
S6 1 9 6.9b 1.0 4.6b 1.05
S7 1 3 3.3 0.5 1.4 1.61
D1 2 15 4.8 0.8 3.2 0.67b
D2 2 5 6.2a 0.7 4.3b 1.00b
C1 2 50 na na na na
C2 2 51 4.4 1.3 3.9 1.56
C3 1 32 4.7 1.4 3.1 0.92b
C4 2 50 4.0 0.6 1.44 2.3
C5 1 47 4.9 1.7 2.9 1.4
Ranges are: total cholesterol, total (desirable: <5.2 mmol/l; borderline high: 5.2–
6.2 mmol/l; high: P6.2 mmol/l); triglycerides (normal: <1.7 mmol/l; borderline
high: 1.7–2.25 mmol/l; high: 2.26–5.64 mmol/l; very high: P5.65 mmol/l); LDL-
cholesterol (optimal: <2.59 mmol/l; low risk: 2.59–3.34 mmol/l; borderline high:
3.37–4.12 mmol/l; high: 4.14–4.90 mmol/l; very high: P4.92 mmol/l) and HDL-
cholesterol (low HDL: <1.04 mmol/l; normal: 1.04–1.55 mmol/l; desirable:
>1.55 mmol/l).
a Borderline high total cholesterol levels.
b Out-of range levels.
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plasma Chol levels resulting in its deposition in the arteries, while
those in the APOB cause failure of its clearance. Such genetic vari-
ants in both genes have been implicated, individually or combined,
in familiar hypercholesterolaemia (FH) among different ethnic
populations.
Apart from the LDLR and APOB, the proprotein convertase sub-
tilisin/kexin type 9a gene (PCSK9), a member of the proteinase K
subfamily of subtilases, is also thought to affect plasma LDL-C
levels by altering LDLR protein levels via a post-transcriptional
mechanism [4–7]. It appears to play an important role in cellular
Chol metabolism by affecting the levels of both LDLR and circulat-
ing APOB-containing lipoproteins in LDLR-dependent and -inde-
pendent fashions [21–23]. More recently, missense mutations in
the PCSK9 have also been linked with ADH [8–11], classiﬁed as
non-LDL non-APOB ADH. However, great variability prevails in
the literature, with some studies suggesting a segregation of a large
number of mutations in the three genes with FH among various
populations [12,28] and others being unable to show such a rela-
tion particularly for PCSK9 [13]. It is likely therefore, that the phe-
notype and severity of FH as well as the ensuing cardiovascular
disease vary among different ethnic groups, or possibly between
individuals within the same family. Besides, it is not known
whether or not other genes regulating pathways indirectly related
to lipid metabolism may also be linked to HFH. Hence, this study
was designed to identify the chromosomal linkage to HFH and
characterize the gene polymorphisms associated with HFH-related
CAD manifestation in a Saudi family with clinical manifestation of
FH and the propositus harbouring premature CAD.2. Materials and methods
2.1. Study cases
The propositus (S3), the third of seven sons and two daughters
born to unrelated parents underwent triple coronary artery bypass
surgery at the age of 15 years. On admission, this index case had
reported with a chest wound and xanthomas, clinical features of
bilateral carotid artery disease and a very severe form of familial
hyperlipidemia, harbouring Chol level of 10.1 mmol/L (desirable:
<5.2 mmol/l) and LDL-C level of 7.9 mmol/L (optimal: <2.59
mmol/l), in addition to low HDL-C (0.51 mmol/l; Normal: 1.04–
1.55). The father had the features of borderline HFH (Chol,
6.1 mmol/L; LDL 4.0 mmol/L), while the mother, two other sons
(S4 and S6) and a daughter (D2) presented with clinical pheno-
types of the disease [combination of high Chol (P6.2 mmol/L)
and high LDL-C (P4.12 mmol/L)] (Table 1). In addition to the four
affected siblings and the mother, two other sons having otherwise
normal Chol and LDL-C levels also exhibited low HDL-C levels
(<1.04 mmol/L). None of the family members had isolated elevated
LDL-C levels. Five individuals randomly selected from our CAD Reg-
istry were ﬁrst included as controls, and then a further 70 recruited
to verify some of our ﬁndings on the HDL-C status. The criteria for
the diagnosis of FH were adapted from our Institutional Guidelines,
employing the reference values approved by the USA National Cho-
lesterol Education Program (NCEP). This study was performed in
accordance with the regulations prescribed by our Institutional
Ethics Committee and all participants signed an informed consent.
2.2. Linkage analysis for familial hypercholesterolemia
Five milliliter of peripheral blood was sampled in EDTA tubes
from each of the study individuals after obtaining their written
consent. Genomic DNA was extracted from leukocytes by the stan-
dard salt methods using PUREGENE DNA isolation kit (Gentrasystem, Minneapolis, MN, USA), and for the genome-wide scanning
performed using the Affymetrix Gene Chip 250 sty1 mapping array
(Affymetrix, Inc., Santa Clara, CA, USA). Brieﬂy, 250 ng of genomic
DNA was digested with the restriction endonuclease StyI and
mixed with Sty1 adaptors and ligated with T4 DNA ligase. The mix-
ture was then added to four separate PCR reactions, ampliﬁed,
pooled and puriﬁed to remove the unincorporated dNTPs. The
PCR product was then fragmented, end-labelled with biotin,
hybridized to the 250 sty1 array for 18 h, washed, stained and
scanned as recommended by the manufacturer. SNP genotypes,
linear chromosomal locations and marker ordering were detected
with the Affymetrix GeneChip Genotyping Analysis Software
(GTYPE) Version 4.0.
Multipoint parametric linkage analysis was performed using
the GeneHunter Easy Linkage analysis software 4.0 (Affymetrix,
Inc., Santa Clara, CA, USA) for estimating the LOD scores. Both auto-
somal recessive and dominant models of inheritance were used to
search chromosomal linkage regions, using Asian SNP allele fre-
quencies. Copy Number Analyzer for GeneChip Ver. 3.0 (CNAG)
(Affymetrix, Inc., Santa Clara, CA, USA) was employed to check
the shared chromosomal regions for homozygosity.
2.3. Screening for mutations
All exons and intron–exon junctions of the genes of interest
were genotyped by sequencing using the MegaBACE DNA analysis
system (Amersham Biosciences, Sunnyvale, CA, USA). Brieﬂy, 5 ll
of PCR product were treated with 2 ll of ExoSAP-IT (USB Corpora-
tion, Cleveland, OH, USA) at 37 C for 30 min to allow the hydro-
lytic removal of excess primers and dNTPs by Exonuclease 1 and
Shrimp Alkaline phosphatase. The enzymes were inactivated at
80 C for 15 min, and the sequencing reaction was initiated by mix-
ing 2 ll DNA, 1 ll of 5 lmol primer, 8 ll of DYEnmic ET Dye Termi-
nator (Amersham Biosciences, Buckinghamshire, UK) and 9 ll of
distilled water. The mixture was thermally cycled 40 at 95 C
for 20 s, 50 C for 15 s, and 60 C for 1 min. Unincorporated dye-la-
belled terminators were removed by gel-ﬁltration through the
DyeEx 96 plate (Qiagen, GmbH, Hilden Germany). The eluent was
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Healthcare UK Ltd., Little Chalfont, Buckinghamshire, UK) for
sequencing. Data was analyzed for SNPs by both Chromaspro pro-
gram (Technelysium Pvt. Ltd., Tewantin, Qld, Australia) and Laser-
gene software (DNASTAR, Inc. Madison, WI, USA).
2.4. Statistical analysis
All statistical analyses were performed using the SPSS software
version 14 (SPSS Inc., Chicago, USA). A two-tailed p value <0.05 was
considered statistically signiﬁcant.
3. Results
The ﬁrst step of this study was to identify chromosomal loci
linked to HFH using both the autosomal recessive and dominant
models by whole genome scanning approach. Scanning for homo-
zygosity in the affected family members with the Affymetrix 250
sty1 chip yielded several peaks in different chromosomes (Chr)
including chr1, 2, 5, . . . isolating at least three of affected siblings
(S4, S6 and D3) for both models (Supplementary Table 1) using
the autosomal dominant model. Interestingly, all models placing
the propositus together with other members of the family almost
always yielded no results. However, CNAG analysis showed peaks
on Chr 12 and 13 isolating him individually and on Chr 15 together
with two other affected siblings. It is also noteworthy that the
dominant model did not isolate chr19, which harbours the LDLR
gene, either as a potential locus for HFH or homozygous for the
propositus and any other family members.
Based on currently available data however, we elected to ﬁrst
sequence all the coding areas including the intro–exon junctions
of the LDLR gene (ENSG00000130164) as the most likely candidate
for the early onset of CAD. Eleven single nucleotide polymorphismsTable 2
Low-density lipoprotein receptor genotyping in family with heterozygote familial hyperlip
SNP AA FT MT S1 S2 S3 S4 S
rs2228671C > T C27T C/T C/C C/C C/T C/C C/T C
rs5930A > G R471R A/G A/G A/G A/G A/A A/G A
rs688C > T B592B C/T C/T C/T C/T C/C C/T C
rs5925T > C V653V T/C T/C T/C T/C T/T T/C T
rs2738466 A > G UTR A/G A/G A/G A/G G/G A/G A
ns43237T/C UTR T/C T/C T/C T/C C/C T/C T
ns43280C > A UTR C/A C/A C/A C/A A/A C/A C
rs5742911A > G UTR A/G A/G A/G A/G G/G A/G A
rs17249057 T > C UTR T/C T/C T/C T/C C/C T/C T
rs17249064 G > T UTR G/T G/T G/T G/T T/T G/T G
rs2738467 C > T UTR C/T C/T C/T C/T C/C C/T C
The table shows the SNPs identiﬁed in the coding region of LDLR in the family. FT, fath
controls as C1–C5. Novel mutations are denoted with ns(+nucleotide position relative to
Table 3
Apolipoprotein B genotyping in family with heterozygote familial hyperlipidemia.
SNP AA FT MT S1 S2 S3 S4
rs679899C > T A618V C/C T/T C/T C/T C/T C/T
rs676210C > T P2739L C/T C/T C/T C/C T/T T/T
rs12720854A > G S3279C A/G A/A A/G A/G A/A A/A
ns38467C > T T3754I C/C C/T C/C C/T C/C C/C
ns41147–/G 4165del –/G –/G –/G G/G –/G –/G
rs1042031G > A E4181K G/G G/A G/G G/A G/G G/G
rs1042034G > A S4338B G/A G/A G/A A/A G/G G/G
rs12713450C > T T4484M C/T C/C C/T C/T C/C C/C
The table shows the SNPs identiﬁed in the coding area of the apolipoprotein B in the stud
D1 and D2 and controls as C1–C5. AA, amino acid; novel mutations are denoted with n(SNPs) were found in the LDLR in the cohorts. Two of these SNPs
signiﬁed novel mutations consisting of a T > C change at nt43237
and C > A change at nt43279 in the untranslated region of the gene
(Table 2). Five others were familiar SNPs residing in the 30-untrans-
lated region. Most remarkably, the index case carried the homozy-
gous mutant alleles for all SNPs. In direct contrast, the only
normolipidemic sibling (all three lipid levels in the normal range)
carried the homozygous wildtype alleles for all, except for the
rs2228671C > T (p.Cys27Thr) and ns4380C > A for which he was
heterozygous. Thus, a diametrically contrasting pattern in the LDLR
SNPs was delineable at nine positions between the propositus and
the disease-free sibling. Furthermore, both parents were heterozy-
gous for all SNPs, except rs2228671 for which the mother was a
C/C carrier (p.Cys/Cys). Interestingly also, the other carriers of this
genotype comprising three affected (S4, S6 and D2) and one unaf-
fected off-spring (S1) also harboured low-to-borderline HDL-C lev-
els like the mother. Even more signiﬁcant in this regard, was the
observation that a control subject carrying the C/C genotype also
exhibited low HDL-C, thus pointing to the isolation of this geno-
type with the reduction in HDL-C level, in general. In order to test
the general applicability of this ﬁnding, we genotyped 70 individ-
uals with clinical manifestation of low HDL-C levels randomly se-
lected from our CAD registry. Interestingly, the study
demonstrated that 52(74.3%) were homozygous for the C allele,
17(24.3%) were C/T carriers and only 1(1.4%) carried the T/T geno-
type, unequivocally linking the p.Cys/Cys to the presence of low
DHL-C levels.
Two of the other loci picked individually by the chips on Chr 1
and 2 contain the PSCK9 and APOB, genes, respectively, both of
which are also candidate genes for FH. We were keen to further
screen for possible association of these genes with HFH in our
family. In the APOB(ENSG00000084674), we identiﬁed 8 SNPs
altogether, two of which (ns28G > T, ns405 G > A) were novelidemia.
5 S6 S7 D1 D2 C1 C2 C3 C4 C5
/T C/C C/T C/T C/C C/T C/C C/C C/T C/C
/G A/G G/G A/G A/G G/G G/G A/A A/G A/G
/T C/T T/T C/T C/T T/T C/T C/C C/T C/T
/C T/C C/C T/C T/C C/C T/C T/T T/C T/C
/G A/G A/A A/G A/G A/G A/A A/A A/G A/A
/C T/C T/T T/C T/C T/C T/T T/T T/C T/T
/A C/A C/A C/A C/A C/A C/C C/C C/A C/A
/G A/G A/A A/G A/G G/G A/A A/A G/G A/A
/C T/C T/T T/C T/C T/C T/T T/T T/C T/C
/T G/T G/G G/T G/T G/T G/G G/G G/T G/T
/T C/T T/T C/T C/T C/T C/T C/C C/T C/T
er; MT, mother; Male off-springs are denoted as S1–S6, females as D1 and D2 and
the gene). AA, amino acid; UTR, untranslated region.
S5 S6 S7 D1 D2 C1 C2 C3 C4 C5
C/T C/T C/T C/T C/T T/T C/C C/C T/T C/T
C/C C/C C/C C/T T/T C/T C/T C/T T/T T/T
A/G A/G A/G A/A A/A A/A A/A A/G A/A A/A
C/T C/T C/T C/T C/C C/C C/C C/C C/C C/C
–/G –/G –/G –/G –/G –/G –/G –/G G/G –/G
G/A G/A G/A G/A G/G G/A G/G G/G G/G G/G
A/A A/A A/A G/A G/G G/A G/A G/A G/G G/G
C/T C/T C/T C/C C/C C/C C/C C/T G/C C/C
ied family. FT, father; MT, mother; male off-springs are denoted as S1–S6, females as
s(+nucleotide position relative to the gene).
Table 4
Protein convertase subtilisin/kexin type 9 genotyping in family with heterozygous familial hyperlipidemia.
SNP AA FT MT S1 S2 S3 S4 S5 S6 S7 D1 D2 C1 C2 C3 C4 C5
ns28 G > T prom G/T T/T G/T G/T G/T G/T G/G G/G G/T G/T G/T G/G T?T T/T G/G G/G
ns405 G > A E39K G/A G/A G/G G/A G/G G/G G/G G/G G/A G/G G/G G/G G/G G/G G/G G/G
rs28385701 C > T S47S C/T C/C C/T C/C C/T C/C C/C C/C C/T C/C C/C C/C C/C C/C C/C C/C
rs540796 A > G V460V G/G A/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G
rs562556 G > A V474I A/A G/A G/A G/A G/A G/A G/A A/A A/A A/A G/A G/A G/G G/G G/G G/G
rs662145 C > T Utr T/T C/T C/T C/T C/T C/T C/T C/T T/T C/T C/T C/T C/T C/T C/C C/T
The table shows the coding SNPs identiﬁed in the protein convertase subtilisin/kexin type 9 in the family. FT, father; MT, mother; male off-springs are denoted as S1–S6,
females as (D1 and D2) and controls as (C1–C5). Novel mutations are denoted with ns(+nucleotide position relative to the gene). AA, amino; Utr, untranslated region.
P. Muiya et al. / International Journal of Diabetes Mellitus 1 (2009) 16–21 19(Table 3). Notably, the proband and two other affected siblings (S4
and D2) shared homozygosity for 7 of the variants. Among these
SNPs, the rs676210C > T represents a change to homozygous mu-
tant allele leading to Leu2739Leu, of which both parents carried
the heterozygote Pro2739Leu. Furthermore, three of these SNPs
were common among the heterozygote carriers, and one each
was shared with either of the parents. This ﬁnding pointed to a
high level of heterogeneity of the APOB mutant genotypes in the
family, possibly depicting an autosomal dominant nature of the
disease in the family.
We then embarked on further searching for the possibility that
the PCSK9 gene may also isolate with some of the phenotypic fea-
tures of the present family. Of the 6 SNPs discovered in the PCSK9
(ENSG00000169174), two (nt28G > T, nt405G > A) were novel
mutations (Table 4). Notably, all of the off-springs harbouring
low HDL-C levels were heterozygous for the nt28G > T mutation,
possibly linking it with reduction in HDL-C in general. Other un-
ique features included the sharing of Lys39Lys primarily by the af-
fected off-springs at which the parents carried the Glu39Lys and
that of the Val474Ile by three of these individuals with the mother,
also possibly pertaining to the autosomal dominance and hetero-
geneity of the disease.
4. Discussion
In the present study, we ﬁrst employed the whole genome link-
age strategy to identify chromosomal loci exhibiting homozygosity
for HFH in a family with evidence of FH. This approach pointed to a
number of putative regions of the genome as potential candidates.
However, these tests could not identify loci shared by the proband
with any of the affected members of the family, pointing to the
likelihood of unique sequences being responsible for early onset
of CAD in this individual. It is also noteworthy that heterozygous
and complex disorders such as HFH or CAD often fail to demon-
strate delineable linkage on currently available platforms. Hence,
our approach for searching the potential candidate genes was
based on available data which implicate particularly three genes,
the LDLR, APOB and PSCK9, as the most likely candidates. Sequenc-
ing of the coding regions of these genes resulted in the identiﬁca-
tion of several novel as well as familiar point mutations in all three
genes in the studied family. Of the three genes, the LDLR exhibited
the highest level of polymorphic changes. We identiﬁed homozy-
gosity for the minor alleles of seven of the SNPs (haplotype) in
the propositus in direct opposition to the homozygosity for the
wildtype genotypes of the same SNPs in a disease-free sibling. This
ﬁnding strongly points to a link for at least some, if not all, of the
minor alleles of these SNPs with the elevation in Chol and LDL-C
levels in the primary proband. Since no other family member car-
ried this unique combination of the alleles, it can be inferred that
the amalgamation of these point mutations, together or partially
at least as a haplotype, unequivocally isolates this individual from
the rest of the family. More importantly, it can further be specu-
lated that this haplotype(s) is the probable culprit for the severityof the HFH, and therefore early onset of CAD. To our knowledge, no
similar allelic combination has been described yet with respect to
premature CAD or HFH.
Two of the LDLR SNPs constituting part of the implicated haplo-
type are novel, while causative role(s) have been ascribed to at
least ﬁve of the familiar ones with respect to CAD or hyperlipidae-
mic disorders to date. It should also be noted that both parents and
all of the affected siblings were heterozygous for almost all of these
mutations, possibly implicating these variants as contributing to
the manifestation of HFH in this family. Recently, three familiar
LDLR SNPs described in the present study (rs688C > T, rs5930A > G
and rs5925T > C) have also been discussed as potential risks for
dyslipidemic disorders [14,15]. Therefore, our results can be seen
as partly conﬁrming the role of these SNPs in HFH in general.
Moreover, as mentioned previously, several other LDLR mutations
have also been associated with FH in different populations [5,6],
and severity of HFH was partly attributed to homozygosity in this
gene [11,14,16].
Among the alterations discovered in the LDLR gene, only the
rs2228671C > T in exon 1 yields a change in the protein sequence.
Particularly remarkable in this regard was the observation that the
homozygous C/C genotype of this SNP was not only present in the
propositus, but also shared with the mother and three kindreds
who likewise harboured low DHL-C levels. Since this genotype
was dominant in the affected individuals, its involvement in HFH
cannot be completely ruled out. Speciﬁcally, this may explain the
importance of heterozygosity in the LDLR as contributing to the
disease in this family. More importantly however, was the observa-
tion that the only feature shared by the affected off-springs with
two of their non-affected siblings carrying the p.Cys27Cys was
the harbouring of low HDL-C levels. This observation strongly
implicates this phenotype in a causative fashion for the reduction
in HDL-C concentrations. Furthermore, the fact that an unrelated
individual carrying the p.Cys27Cys variant also had low DHL-C
concentrations pointed to a general applicability of this phenome-
non in the general population. Indeed, our conﬁrmatory study to
test the notion of this constituting a general phenomenon related
to low HDL-C levels, unequivocally isolated this mutation as con-
tributing to events leading to the reduction in HDL-C levels in
our population in general. Interestingly, one study has associated
the T allele of this SNP (p.Thr27Thr) with reduction in LDL-C levels
[17], while the Cys27Cys in combination with other SNPs has been
linked with an elevation in Chol levels [15]. Put together however,
these ﬁndings appear to further link homozygosity at this gene lo-
cus with various forms of events leading to perturbations in cho-
lesterol homeostasis. Possible implications are therefore that this
motif is involved in yet unidentiﬁed mechanism(s) directly regu-
lating Chol metabolic pathways. Hence, the variations in the ﬁnd-
ings among different ethnic groups can be viewed as reﬂective of
the heterogeneity in the underlying genetic causes of the disease.
The other gene of interest, the APOB, also exhibited several point
mutations in our study family, which included two novel ﬁndings.
Among the interesting features of these changes was the sharing of
20 P. Muiya et al. / International Journal of Diabetes Mellitus 1 (2009) 16–21several variants by three of the affected individuals. While the pre-
cise role of these combinations of mutations needs to be eluci-
dated, it can be speculated that these mutations exert an impact
on the manifestation of HFH, in a fashion that is probably depen-
dent on the prevalence of other factors. The rs676210C > T
(p.P2739L) has been association with variability in Chol level in
the general population [18] while the rs679899, rs1042034,
rs1042031 and 10699G > A (p.R3500Q), have been discussed with
respect to variations in HDL-C and LDL-C levels [15,19]. Probably
the most well studied of these is the R3500Q (currently denoted
as R3527Q), which has been associated with FH [20–24] as well
as other forms of hypercholesterolemia [25–27] in various ethnic
groups. Its role in dyslipidemic disorders appears to be well char-
acterized. In the present study, however, this mutation was not de-
tected, dissociating it from the phenotypes in the family. To our
knowledge, there is hardly any other data pertaining to a possible
role of the other SNPs in FH. It is nonetheless noteworthy that com-
binations of mutations in the APOB were associated with the de-
crease of HDL-C levels in the same individuals that harboured
the Cys27Cys in the LDHR as well as high Chol and LDL-C levels.
The fact that mutations in two separate genes were simultaneously
related to a reduction in HDL-C levels combined with the observa-
tion that unrelated individuals carrying the same Cys27Cys had a
similar phenotype pointed to a general phenomenon linked to
the reduction in HDL-C concentrations.
Like the APOB, the PCSK9 gene displayed heterogeneity in the
distribution of mutations among the study cohorts. In contrast to
APOB, however, no particular delineation of the trends in the rela-
tionship of the SNPs could be established with the disease. More-
over, since none of the individuals presented with isolated
elevated LDL-C, the presence of ADH in this family might be pre-
cluded. Besides, none of the family members appeared to have
hypocholesterolemia, and the type and severity of hyperlipidemia
varied among the subjects. On the other hand, three of the PCSK9
SNPs described here (rs28385701, rs540796 and rs562556) have
also been previously discussed as risk factors for hyperlipidemia
[28]. Our study does not necessary preclude these SNP as potential
candidates for HFH in this family. Moreover, there are other muta-
tions in the PCSK9 gene absent in our case study that have also
been linked with changes in LDL-C levels [8,12] and the severity
of CAD [19] in different ethnical groups. It appears therefore that
mutations in the PCSK9 may exert different effects on Chol han-
dling in hyperlipidemic disorders.
Overall, our results point to various SNPs in the studied genes
individually or combined as being responsible for some of the
forms of FH. Similar combinations of polymorphic changes have
also been described previously in the three genes in individuals
with FH [29–33]. For example, some rare missense mutations of
PCSK9 are thought to negatively enhance the clinical phenotypes
of patients carrying LDLR mutations [34–36]. Also, a meta-analysis
identiﬁed a number of genes including LDLR and PCSK9 as present-
ing common risks for hyperlipidemia and CAD [37]. Therefore, our
results strongly furnish support for a link for these changes with
the mechanisms regulating Chol at various levels. The impact of
PSCK9 on ADH or familial hypocholesterolemia, is thought to be a
result of a gain [34] or loss [38,39] of function of the gene in elic-
iting the degradation of the LDLR protein [40]. To this effect, it
should be noted that mechanistically, PCSK9 promotes the degra-
dation of the LDLR in hepatocytes apparently both intracellularly
and through its secretion and binding onto the receptor leading
to its internalization [41,42]. A plethora of possible mechanisms
has been hypothesized, and it is now accepted that PCSK9 regu-
lates LDLR post-transcriptionally. One school of thought purports
that PCSK9 may affect both the level of LDLR and that of circulating
APOB-containing lipoproteins in an LDLR-dependent and -indepen-
dent fashion [41]. In the latter case, the incidence of CAD is re-duced, thereby demonstrating that low LDL-C levels from birth
are highly beneﬁcial [38]. Apparently, PSCK9 polymorphism may
also inﬂuence Chol levels indirectly, related to an overproduction
of APOB [23]. Accordingly, the PCSK9 variants linked with FH would
inﬂuence the secretion of APOB-containing lipoproteins, possibly
explaining the marked increase in circulating LDL in heterozygous
carriers [43]. It has been further suggested that the LDLR is the
dominant partner in regulating the cellular trafﬁcking of PCSK9,
whereby the later promotes the degradation of the LDLR by an
endocytotic mechanism [41]. Based on this, it has been argued that
PCSK9 mutations could be important factors that cumulatively
inﬂuence plasma LDL-C levels in the general population [44].
However, several questions concerning its mode of action re-
main unanswered. In particular, it remains unknown whether it
acts directly on the LDLR or activates another protein that in turn
causes degradation of the receptor. Nonetheless, intuitively the
presence of combinations of such mutations in these genes is in-
deed likely to be detrimental. Altogether therefore, the ﬁnding of
common mutations in at least two genes shared by the individuals
with HFH and/or low HDL-C levels add to the continually growing
body of data supporting the presence of hyperlipidemic risk at var-
ious chromosomal loci and furnish justiﬁcation for further studies
in these regions to facilitate the identiﬁcation of the actual causa-
tive alleles that may be of clinical value. In particular, the possibil-
ity that an LDLR haplotype may signify manifestation of CAD in
HFH provides a plausible basis for early screening for premature
CAD in patients with FH. Recently, efforts have been directed at
identifying potential clinical value for some of the mutations found
in the three genes as diagnostic tools for familial hypercholesterol-
emia [45–52]. It is also thought that patients homozygous or com-
pound heterozygous for LDLR mutations or double heterozygous
for LDLR and APOB mutations have higher LDL-C levels, more
extensive xanthomatosis and more severe premature CAD than
simple heterozygotes for mutations in either these genes or for
missense mutations in PCSK9 gene.
In summary, we have identiﬁed several novel mutations that
isolate with heterozygote hyperlipidemia in a Saudi family with
high prevalence of hyperlipidemia. The results demonstrate a hap-
lotype in the LDLR that is strongly associated with premature CAD
as well as an independent SNP that may be related to the reduction
in DHL-C in this family. It can be concluded that the manifestation
of HFH and early onset of CAD may be primarily due to the muta-
tions in LDLR under these conditions. The differences between the
proﬁles of mutations found in the present study and those discov-
ered in other studies imply that there are variations in combina-
tions of mutations responsible for FH in different ethnical groups.
It is therefore important to identify the pattern of the SNPs for
the individual genes in order to procure the correct clinical data-
base for diagnostic and possibly therapeutic purposes for the indi-
vidual population of interest.
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